

Mallappa, Ashwini

Ashwini Mallappa, MD, is an Associate Research Physician with the Pediatric Service, Section on Congenital Disorders, at the National Institutes of Health (NIH) Clinical Center, Bethesda, Maryland. Dr. Mallappa received a Bachelor of Medicine and Bachelor of Surgery (MBBS) from graduate of Rajiv Gandhi University of Health Sciences, India. Following her graduation from medical school she completed her residency at Crozer Chester Medical Center (then affiliated with Children's Hospital of Philadelphia), Pennsylvania and fellowship in Pediatric Diabetes and Endocrinology at the University of Oklahoma Health Sciences Center, Oklahoma. She joined the NIH Clinical Center in 2012 and also serves as a Faculty member of the Pediatric Endocrinology Training Program at the NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development.

Dr. Mallappa's research is in the area of congenital adrenal hyperplasia (CAH), a rare lifethreatening autosomal recessive disorder of the adrenal gland. She has extensive clinical expertise in the management of CAH. She plays a lead role in the natural history study of CAH at the NIH Clinical Center and is currently working on numerous CAH-related projects including clinical trials testing novel treatment approaches for CAH. She was Lead Associate Investigator of the Phase 2 study of Chronocort®, a modified-release hydrocortisone capsule formulation and Site Lead Associate Investigator of a multicenter Phase 3 study of Chronocort®. She recently completed a Phase 2 pilot study of cortisol replacement via subcutaneous hydrocortisone infusion using a programmable pump in adults with CAH. These clinical trials are aimed at mimicking cortisol circadian rhythm along with addressing the adrenocorticotrophic hormone-driven excess androgen production seen in individuals with CAH. Dr. Mallappa is also part of a multi-site study of Abiraterone acetate in the treatment of pre-pubertal children with CAH.